AR and benign prostatic hyperplasia: However, as is common practice for BPH, all patients were exposed to medications affecting AR activity prior to surgery (5-alpha reductase inhibitors), making it unclear whether AR target gene changes were due to intrinsic properties of BPH or prior therapy.